PUBLIC COMPANY
save$OVIDOvid Therapeutics Inc.
$OVID2.2600+1.80%New York, NY, USupdated 10h ago
community read0 votes
🐶 often sniffed alongside
top 3pipeline
2
marketed
0
phase 3
0
catalysts ytd
6
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 11Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (2) · pdufa (1)
🐶 Hiring Signal
News
- China has a clear shot to 2030 goals, though economic, cultural barriers remainTo grow into a biopharma juggernaut, China aims to become the leading source of innovative medicines on the global markets—a goal that experts say the country is on track to hit.biospace · 8d ago
- Without US action on China’s innovation blitz, biotech leaders see a Rust Belt futurePolicy uncertainty is hampering the growth of U.S. biotech as China rises thanks to carefully planned investment in the industry, experts said during a BioSpace webinar.biospace · 8d ago
- UniQure gets an FDA decision date; Teva scraps brain drug studyThe FDA appears likely to hold an advisory committee for UniQure’s closely watched Huntington’s disease gene therapy. Elsewhere, a biotech’s share price was cut in half following a regulatory setback.biopharma_dive · 15d ago
- China tightens grip on biotech platform ownership but foreign licensing deals still okayThe new policy signals an escalation by the Chinese government on biopharma deals but is unlikely to have a major impact given that the vast majority of foreign interest in Chinese biotech comes in…biospace · 1mo ago
- Webinar: The China question: Can US biotechs lead as investment heads east?In this webinar, BioSpace will gathered experts to discuss China’s impact on the future of biotech and how both U.S. and Chinese companies can thrive—and maybe even collaborate.biospace · 1mo ago
- China’s surging biotech sector represents both competition and lifeline for the USAs Chinese companies push beyond “me-too” drugs and the country lays out a new five-year plan targeting a $522 billion–strong biotech industry by 2030, experts say more predictable funding and regu…biospace · 1mo ago
- Rare disease reform, CMC risk, reshoring US trials top of mind ahead of PDUFA VIII meetingThe FDA gathers Wednesday to hear what industry stakeholders and the public want included in the latest iteration of the Prescription Drug User Fee Act that sets the agency’s priorities for fiscal…biospace · 2mo ago
- For PDUFA VIII, the most valuable incentive may be timeThe FDA’s proposal to offer 50% off application fees for drugs with early-stage trials conducted in the U.S. is unlikely to achieve the intended result. What biotechs really want is speed.biospace · 2mo ago
- Ovid and Takeda's epilepsy drug gets new life at Perceptive-backed NewCoAbout 26 months after failing two Phase 3 trials, an epilepsy treatment candidate is getting plucked off biopharma's shelves and will be given a new chance at life. Life sciences investment firm Pe…endpoints · 3mo ago
- FDA’s leadership void leaves biotech with renewed ‘uncertainty’Marty Makary's resignation leaves the agency with temporary directors in three top positions, and a number of newly instituted policies with an unclear future.biopharma_dive · 6mo ago
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that